Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPS phase II lenvatinib study in advanced parathyroid carcinoma
KCT0012606Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in parathyroid cancer, sponsored by Boryung. Primary endpoint: Objective Response Rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
parathyroid cancer
Beyond the preview
Go deeper on KCT0012606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012606.